Navigation Links
iCardiac Selected for Multiple Cardiac Safety Studies
Date:6/15/2009

Continues Market Leadership in Highly Automated QT(sm) Evaluation and Helps Sponsors Avoid False Positives

Rochester, NY (PRWEB) June 15, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that it has been chosen by a medium sized pharmaceutical company for cardiac safety evaluation comprising multiple Thorough QT (TQT) Studies.

iCardiac will use its FDA accepted Highly Automated QT method for all contracted studies in addition to using iCardiac's QTbtb(sm) method for avoiding false positives. The sponsor selected iCardiac because of both iCardiac's cardiac safety expertise in relation to complex drug development programs as well as the extensive validation of iCardiac's COMPAS technology. COMPAS Highly Automated QT leads the industry in validation and deployments covering over 1.5 million ECGs analyzed with partners including pharmaceutical companies, academia, regulators, as well as having been cross validated with result from five leading ECG core labs.

"We are enthusiastic about the markets continued acceptance of iCardiac's Highly Automated QT solution," said Sasha Latypova, Executive Vice President. "In addition to increasing the robustness of cardiac safety evaluation and reducing the likelihood of false positives through the use of iCardiac's proprietary QTbtb method, the sponsor will realize increased economic efficiencies in comparison to traditional QT studies."

About iCardiac Technologies:
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/tqt/cardiacsafety/prweb2526064.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Reports Significant Revenue Growth and Profitability
2. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
3. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
4. Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner
5. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
6. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
7. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Solazyme Selected for National Institute of Standards and Technology Award
10. Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America
11. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... ... FireflySci Inc. is a go-getter type of company that continues to grow ... main factors. The first is the amazing customer service that the FireflySci staff ... around the world. , 2016 was a tremendous sales year for FFS and much ...
(Date:1/19/2017)... 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), ... for operable and inoperable solid tumor cancers, announced today ... of NW Bio, will present at the Phacilitate Immunotherapy ... Hyatt Regency Hotel in Miami, Florida ... entitled "New Therapeutic Approaches – Expanding the Reach of ...
(Date:1/18/2017)... OR (PRWEB) , ... January 18, 2017 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 ... Cyclone V E FPGA into a compact business-card sized form factor suitable for ...
(Date:1/18/2017)... Jan. 18, 2017 Applied BioMath ( ... to drug research and development, today announced that ... and CEO of Applied BioMath, will present at ... Modeling (BAGIM) Meeting on Thursday January 19, 2017 ... , MA.   Dr. Burke,s talk "Quantitative Modeling ...
Breaking Biology Technology:
(Date:1/19/2017)... Jan. 19, 2017 Sensory Inc ... and security for consumer electronics, and i ... systems and cybersecurity solutions, today announced a global ... financial institutions worldwide to bolster security of data ... secure user authentication platforms they offer, innerCore now ...
(Date:1/12/2017)... SAN DIEGO , Jan. 12, 2017  Trovagene, ... circulating tumor DNA (ctDNA) technologies, today announced that it ... Europe and the Middle ... biopsy tests.  This milestone marks the first wave of ... tests for urine and blood samples. The ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
Breaking Biology News(10 mins):